• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Market characteristics o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Five forces summary o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Route of administration o Market segments o Comparison by Route of administration o Topical - Market size and forecast 2019-2024 o Oral - Market size and forecast 2019-2024 o Parenteral - Market size and forecast 2019-2024 o Market opportunity by Route of administration • Customer Landscape • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o Asia - Market size and forecast 2019-2024 o ROW - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography o Market drivers o Market challenges o Market trends • Vendor Landscape o Vendor landscape o Landscape disruption o Competitive Scenario • Vendor Analysis o Vendors covered o Market positioning of vendors o Abbott Laboratories o Bayer AG o Eisai Co. Ltd. o Gilead Sciences Inc. o GlaxoSmithKline Plc o Glenmark Pharmaceuticals Ltd. o Johnson & Johnson o Merck & Co. Inc. o Pfizer Inc. o Sanofi • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibit • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2019 - 2024 ($ million) • 13: Global market: Year-over-year growth 2019 - 2024 (%) • 14: Five forces analysis 2019 & 2024 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2019 • 21: Other1 - Market share 2019-2024 (%) • 22: Comparison by Other1 • 23: Topical - Market size and forecast 2019-2024 ($ million) • 24: Topical - Year-over-year growth 2019-2024 (%) • 25: Oral - Market size and forecast 2019-2024 ($ million) • 26: Oral - Year-over-year growth 2019-2024 (%) • 27: Parenteral - Market size and forecast 2019-2024 ($ million) • 28: Parenteral - Year-over-year growth 2019-2024 (%) • 29: Market opportunity by Other1 • 30: Customer landscape • 31: Market share by geography 2019-2024 (%) • 32: Geographic comparison • 33: North America - Market size and forecast 2019-2024 ($ million) • 34: North America - Year-over-year growth 2019-2024 (%) • 35: Europe - Market size and forecast 2019-2024 ($ million) • 36: Europe - Year-over-year growth 2019-2024 (%) • 37: Asia - Market size and forecast 2019-2024 ($ million) • 38: Asia - Year-over-year growth 2019-2024 (%) • 39: ROW - Market size and forecast 2019-2024 ($ million) • 40: ROW - Year-over-year growth 2019-2024 (%) • 41: Key leading countries • 42: Market opportunity by geography ($ million) • 43: Impact of drivers and challenges • 44: Vendor landscape • 45: Landscape disruption • 46: Industry risks • 47: Vendors covered • 48: Market positioning of vendors • 49: Abbott Laboratories - Overview • 50: Abbott Laboratories - Business segments • 51: Abbott Laboratories - Key offerings • 52: Abbott Laboratories - Key customers • 53: Abbott Laboratories - Segment focus • 54: Bayer AG - Overview • 55: Bayer AG - Business segments • 56: Bayer AG - Key offerings • 57: Bayer AG - Key customers • 58: Bayer AG - Segment focus • 59: Eisai Co. Ltd. - Overview • 60: Eisai Co. Ltd. - Business segments • 61: Eisai Co. Ltd. - Key offerings • 62: Eisai Co. Ltd. - Key customers • 63: Eisai Co. Ltd. - Segment focus • 64: Gilead Sciences Inc. - Overview • 65: Gilead Sciences Inc. - Product and service • 66: Gilead Sciences Inc. - Key offerings • 67: Gilead Sciences Inc. - Key customers • 68: Gilead Sciences Inc. - Segment focus • 69: GlaxoSmithKline Plc - Overview • 70: GlaxoSmithKline Plc - Business segments • 71: GlaxoSmithKline Plc - Key offerings • 72: GlaxoSmithKline Plc - Key customers • 73: GlaxoSmithKline Plc - Segment focus • 74: Glenmark Pharmaceuticals Ltd. - Overview • 75: Glenmark Pharmaceuticals Ltd. - Product and service • 76: Glenmark Pharmaceuticals Ltd. - Key offerings • 77: Glenmark Pharmaceuticals Ltd. - Key customers • 78: Glenmark Pharmaceuticals Ltd. - Segment focus • 79: Johnson & Johnson - Overview • 80: Johnson & Johnson - Business segments • 81: Johnson & Johnson - Key offerings • 82: Johnson & Johnson - Key customers • 83: Johnson & Johnson - Segment focus • 84: Merck & Co. Inc. - Overview • 85: Merck & Co. Inc. - Business segments • 86: Merck & Co. Inc. - Key offerings • 87: Merck & Co. Inc. - Key customers • 88: Merck & Co. Inc. - Segment focus • 89: Pfizer Inc. - Overview • 90: Pfizer Inc. - Business segments • 91: Pfizer Inc. - Key offerings • 92: Pfizer Inc. - Key customers • 93: Pfizer Inc. - Segment focus • 94: Sanofi - Overview • 95: Sanofi - Business segments • 96: Sanofi - Key offerings • 97: Sanofi - Key customers • 98: Sanofi - Segment focus • 99: Currency conversion rates for US$ • 100: Research Methodology • 101: Validation techniques employed for market sizing • 102: Information sources • 103: List of abbreviations

Abbott Laboratories, Bayer AG, Eisai Co. Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Sanofi